🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07386860
Starting soon Not applicable

The Effectiveness of Steroid Nasal Drops in the Olfactory Cleft Combined With Olfactory Training for Patients With PIOD

NCT07386860 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Not applicable
Started
2026-03-01
Last updated
2026-02-04

Condition(s) studied

Smell Dysfunction

Investigational drug(s) / intervention(s)

Steroid nasal drops combined with olfactory trainingPlacebo nasal drops combined with olfactory training

Steroid nasal drops combined with olfactory training: The intervention consists of two components: steroid nasal drops and modified olfactory training.

Placebo nasal drops combined with olfactory training: The intervention consists of two components: normal saline nasal drops and modified olfactory training.

Study summary

This study aims to evaluate the effectiveness of hormone nasal drops in the olfactory cleft combined with olfactory training for treating postinfectious olfactory dysfunction (PIOD). The main questions this clinical trial seeks to answer are:

Can the combination of hormone nasal drops and olfactory training improve smell function better than olfactory training alone in PIOD patients? How does this combined treatment work?

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: 1. Prospective enrollment of otolaryngology clinic patients aged 18-65 years with olfactory dysfunction. Diagnosis of post-infectious olfactory dysfunction (PIOD) will be based on the PPOD 2023 criteria. Participants must demonstrate olfactory impairment via Sniffin' Sticks testing, with TDI scores (sum of Threshold, Discrimination, and Identification) meeting: (1) Hyposmia: 16 \< TDI \< 30.75; (2) Anosmia: TDI ≤ 15. 2. Willingness to participate and signed informed consent. Exclusion Criteria: 1. Use of systemic corticosteroids within 4 weeks or intranasal steroids within 2 weeks prior to enrollment. 2. Severe nasal septum deviation, nasal tumors, acute upper respiratory infections, or uncontrolled allergic rhinitis. 3. History of functional endoscopic sinus surgery or other nasal procedures within 12 months. 4. Severe cardiovascular disease, hepatic/renal insufficiency, uncontrolled diabetes, or immune system disorders. 5. Current or planned pregnancy. 6. Investigator-determined inability to comply with study requirements (e.g., memory/behavioral disorders, depression, heavy alcohol use, prior non-compliance).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Dawei Wu Beijing Beijing Municipality

More Peking University Third Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07386860 on ClinicalTrials.gov ↗ ← All trials in China